Company:  DARA BIOSCIENCES, INC. (DARA)
Form Type:  8-K
Filing Date:  10/2/2012 
CIK:  0000919745 
Address:  8601 SIX FORKS ROAD SUITE 160 
City, State, Zip:  RALEIGH, North Carolina 27615 
Telephone:  (816) 914-7027 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.88  
Change: 
0.00 (0.00%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$15.80M
Description of Business
DARA BioSciences, Inc. (NASDAQ: DARA) is a North-Carolina based specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products. Through our acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, we acquired exclusive U.S. marketing rights to our first commercial, FDA-approved proprietary product Soltamox� (tamoxifen citrate) oral solution. Soltamox has been approved by the U.S. Food and Drug Administration (�FDA�) for the prevention and treatment of breast cancer. On September 7, 2012, we entered into a license agreement with Helsinn Healthcare SA (�Helsinn�) to distribute, promote, market and sell Gelclair�, a unique oral gel whose key ingredients are polyvinlypyrrolidone (PVP) and sodium hyaluronate (hyaluronic acid), for the treatment of certain approved indications in the United States. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99
BROKERAGE PARTNERS